A perfect storm: How tumor biology, genomics, and health care delivery patterns collide to create a racial survival disparity in breast cancer and proposed interventions for change

CA Cancer Journal for Clinicians

Volumn 65, Issue 3, 2015, Pages 221-238

  Daly, Bobby ^a   Olopade, Olufunmilayo I ^a  

^a SECTION OF HEMATOLOGY ONCOLOGY   (United States)

Author keywords

breast cancer; disparities research; health services research; precision medicine

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN P53; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; TUMOR MARKER;

AFRICAN AMERICAN; AGE; ARTICLE; BREAST CANCER; CANCER REGISTRY; CANCER RISK; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CAUCASIAN; CLINICAL TRIAL (TOPIC); COMORBIDITY; EPIGENETICS; GENE ACTIVATION; GENE MUTATION; GENOMICS; GERMLINE MUTATION; HEALTH CARE DISPARITY; HEALTH CARE PLANNING; HEALTH CARE POLICY; HEALTH INSURANCE; HISTOPATHOLOGY; HUMAN; INTEGRATED HEALTH CARE SYSTEM; INTERDISCIPLINARY COMMUNICATION; MAMMOGRAPHY; MEDICAL ERROR; METABOLOMICS; OBESITY; ONCOGENE MYC; PATIENT EDUCATION; PRIORITY JOURNAL; RACE DIFFERENCE; RASSF1A GENE; SOMATIC MUTATION; THERAPY DELAY; TRIPLE NEGATIVE BREAST CANCER; TUMOR SUPPRESSOR GENE; BREAST TUMOR; CANCER GRADING; EARLY DIAGNOSIS; EPIDEMIOLOGY; ETHNOLOGY; FEMALE; GENETICS; HEALTH CARE DELIVERY; HEALTH CARE QUALITY; HEALTH DISPARITY; MORTALITY; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; UNITED STATES;

AFRICAN AMERICANS; BREAST NEOPLASMS; DELIVERY OF HEALTH CARE; EARLY DETECTION OF CANCER; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOMICS; HEALTH CARE REFORM; HEALTH STATUS DISPARITIES; HEALTHCARE DISPARITIES; HUMANS; NEOPLASM GRADING; NEOPLASM STAGING; PATIENT PROTECTION AND AFFORDABLE CARE ACT; PROGNOSIS; QUALITY OF HEALTH CARE; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; UNITED STATES;

EID: 84929128699     PISSN: 00079235     EISSN: 15424863     Source Type: Journal    
DOI: 10.3322/caac.21271     Document Type: Article

References (123)

1. Siegel RL, Miller KD, Jemal A,. Cancer statistics. CA Cancer J Clin. 2015; 65: 5-29.
2. National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) stat fact sheets: breast cancer. Surveillance, Epidemiology, and End Results program. seer.cancer.gov/statfacts/html/breast.html. Accessed July 24, 2014.
3. DeSantis C, Jemal A, Ward E, Thun MJ,. Temporal trends in breast cancer mortality by state and race. Cancer Causes Control. 2008; 19: 537-545.
4. DeLancey JO, Thun MJ, Jemal A, Ward EM,. Recent trends in black-white disparities in cancer mortality. Cancer Epidemiol Biomarkers Prev. 2008; 17: 2908-2912.
5. Howlander N, Noone AM, Krapcho M, et al, eds. SEER Cancer Statistics Review, 1975-2011. Bethesda, MD: National Cancer Institute; 2014. seer.cancer.gov/csr/1975-2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014. Accessed February 1, 2015.
6. Hunt BR, Whitman S, Hurlbert MS,. Increasing black:white disparities in breast cancer mortality in the 50 largest cities in the United States. Cancer Epidemiol. 2014; 38: 118-123.
7. National Cancer Institute. State Cancer Profiles. statecancerprofiles.cancer.gov/map/map.withimage.php?00&001&055&02&2&02&0&1&6&0#results. Accessed November 21, 2014.
8. Clarke CA, West DW, Edwards BK, Figgs LW, Kerner J, Schwartz AG,. Existing data on breast cancer in African-American women: what we know and what we need to know. Cancer. 2003; 97 (1 suppl): 211-221.
9. Marie Swanson G, Haslam SZ, Azzouz F,. Breast cancer among young African American women: a summary of data and literature and of issues discussed during the summit meeting on breast cancer among African American women, Washington DC, September 8-10, 2000. Cancer. 2003; 97 (1 suppl): 273-279.
10. Kurian AW, Fish K, Shema SJ, Clarke CA,. Lifetime risks of specific breast cancer subtypes among women in four racial/ethnic groups. Breast Cancer Res. 2010; 12: R99.
11. Iqbal J, Ginsburg O, Rochon PA, Sun P, Narod SA,. Differences in breast cancer stage at diagnosis and cancer-specific survival by race and ethnicity in the United States. JAMA. 2015; 313: 165-173.
12. National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program. Fast stats: breast; 2014. seer.cancer.gov/faststats/selections.php?#Output. Accessed August 6, 2014.
13. Howlander N, Altekruse SF, Li Cl, et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. 2014; 106: pii: dju055. doi: 10.1093/jnci/dju055.
14. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006; 295: 2492-2502: pii: dju055. doi: 10.1093/jnci/dju055.
15. Setiawan VW, Monroe KR, Wilkens LR, Kolonel LN, Pike MC, Henderson BE,. Breast cancer risk factors defined by estrogen and progesterone receptor status: the multiethnic cohort study. Am J Epidemiol. 2009; 169: 1251-1259.
16. Pfeiffer RM, Mitani A, Matsuno RK, Anderson WF,. Racial differences in breast cancer trends in the United States (2000-2004). J Natl Cancer Inst. 2008; 100: 751-752.
17. Elledge RM, Clark GM, Chamness GC, Osborne CK,. Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States. J Natl Cancer Inst. 1994; 86: 705-712.
18. Ademuyiwa FO, Edge SB, Erwin DO, Orom H, Ambrosone CB, Underwood W III. Breast cancer racial disparities: unanswered questions. Cancer Res. 2011; 71: 640-644.
19. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V,. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-call triple-negative phenotype: a population-based study from the California cancer registry. Cancer. 2007; 109: 1721-1728.
20. Ray M, Polite BN,. Triple-negative breast cancer: a view from 10,000 feet. Cancer J. 2010; 16: 17-22.
21. Schwartz AM, Henson DE, Chen D, Rajamarthandan S,. Histologic grade remains a prognostic factor for breast cancer regardless of the number of positive lymph nodes and tumor size: a study of 161,708 cases of breast cancer from the SEER program. Arch Pathol Lab Med. 2014; 138: 1048-1052.
22. Henson DE, Chu KC, Levine PH,. Histologic grade, stage, and survival in breast carcinoma: comparison of African American and Caucasian women. Cancer. 2003; 98: 908-917.
23. Elmore JG, Moceri VM, Carter D, Larson EB,. Breast carcinoma tumor characteristics in black and white women. Cancer. 1998; 83: 2509-2515.
24. Claus EB, Schildkraut JM, Thompson WD, Risch NJ,. The genetic attributable risk of breast and ovarian cancer. Cancer. 1996; 77: 2318-2324.
25. Easton DF, Bishop DT, Ford D, Crockford GP,. Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. Am J Hum Genet. 1993; 52: 678-701.
26. Polite BN, Olopade OI,. Breast cancer and race: a rising tide does not lift all boats equally. Perspect Biol Med. 2005; 48 (suppl): S166-S175.
27. Nanda R, Schumm LP, Cummings S, et al. Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry. JAMA. 2005; 294: 1925-1933.
28. Fackenthal JD, Zhang J, Zhang B, et al. High prevalence of BRCA1 and BRCA2 mutations in unselected Nigerian breast cancer patients. Int J Cancer. 2012; 131: 1114-1123.
29. Donenberg T, Lunn J, Curling D, et al. A high prevalence of BRCA1 mutations among breast cancer patients from the Bahamas. Breast Cancer Res Treat. 2011; 125: 591-596.
30. John EM, Miron A, Gong G, et al. Prevalence of pathogenic BRCA1 mutation carriers in 5 US racial/ethnic groups. JAMA. 2007; 298: 2869-2876.
31. Churpek JE, Walsh T, Zheng Y, et al. Inherited predisposition to breast cancer among African American women. Breast Cancer Res Treat. 2015; 149: 31-39.
32. Ademuyiwa FO, Olopade OI,. Racial differences in genetic factors associated with breast cancer. Cancer Metastasis Rev. 2003; 22: 47-53.
33. Dookeran KA, Dignam JJ, Ferrer K, Sekosan M, McCaskill-Stevens W, Gehlert S,. p53 as a marker of prognosis in African American women with breast cancer. Ann Surg Oncol. 2010; 17: 1398-1405.
34. Shiao YH, Chen VW, Scheer WD, Wu XC, Correa P,. Racial disparity in the association of p53 gene alterations with breast cancer survival. Cancer Res. 1995; 55: 1485-1490.
35. Blaszyk H, Vauigh CB, Hartmann A, et al. Novel pattern of p53 gene mutations in an American black cohort with high mortality from breast cancer. Lancet. 1994; 343: 1195-1197.
36. National Human Genome Research Institute. The Cancer Genome Atlas. cancergenome.nih.gov. Accessed February 6, 2015.
37. International Cancer Genome Consortium. ICGC Cancer Genome Projects. icgc.org. Accessed February 6, 2015.
38. Jiang Y, Cui L, Chen WD, Shen SH, Ding LD,. The prognostic role of RASSF1A promoter methylation in breast cancer: a meta-analysis of published data. PLoS ONE. 2012; 7: e36780.
39. Mehrotra J, Ganpat MM, Kanaan Y, et al. Estrogen receptor/progesterone receptor-negative breast cancers of young African-American women have a higher frequency of methylation of multiple genes than those of Caucasian women. Clin Cancer Res. 2004; 10: 2052-2057.
40. Wei M, Grushko TA, Dignam J, et al. BRCA1 promoter methylation in sporadic breast cancer is associated with reduced BRCA1 copy number and chromosome 17 aneusomy. Cancer Res. 2005; 65: 10692-10699.
41. Wellen KE, Hatzivassiliou G, Sachdeva UM, Bui TV, Cross JR, Thompson CB,. ATP-citrate lyase links cellular metabolism to histone acetylation. Science. 2009; 324: 1076-1080.
42. Di LJ, Fernandez AG, De Siervi A, Longo DL, Gardner K,. Transcriptional regulation of BRCA1 expression by a metabolic switch. Nat Struct Mol Biol. 2010; 17: 1406-1413.
43. Terunuma A, Putluri N, Mishra P, et al. MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis. J Clin Invest. 2014; 124: 398-412.
44. Glinskii AB, Ma S, Ma J, et al. Networks of intergenic long-range enhancers and snpRNAs drive castration-resistant phenotype of prostate cancer and contribute to pathogenesis of multiple common human disorders. Cell Cyle. 2011; 10: 3571-3597.
45. Armstrong K, Micco E, Carney A, Stopfer J, Putt M,. Racial differences in the use of BRCA1/2 testing among women with a family history of breast or ovarian cancer. JAMA. 2005; 293: 1729-1736.
46. Hall M, Olopade OI,. Confronting genetic testing disparities: knowledge is power. JAMA. 2005; 293: 1783-1785.
47. Matthews AK, Cummings S, Thompson S, List M, Olopade OI,. African Americans and genetic testing for susceptibility to inherited cancers: use of focus group interviews to determine factors contributing to participation. J Psychosoc Oncol. 2000; 18: 1-19.
48. Wideroff L, Freeman A, Olsen L, et al. Physician use of genetic testing for cancer susceptibility: results of a national survey. Cancer Epidemiol Biomarkers Prev. 2003; 12: 295-303.
49. Adams SA, Butler WM, Fulton J, et al. Racial disparities in breast cancer mortality in a multi-ethnic cohort in the Southeast. Cancer. 2012; 118: 2693-2699.
50. Menashe I, Anderson WF, Jatoi I, Rosenberg PS,. Underlying causes of the black-white racial disparity in breast cancer mortality: a population-based analysis. J Natl Cancer Inst. 2009; 101: 993-1000.
51. Chu KC, Lamar CA, Freeman HP,. Racial disparities in breast carcinoma survival rates: separating factors that affect diagnosis from factors that affect treatment. Cancer. 2003; 97: 2853-2860.
52. DeSantis C, Naishadham D, Jemal A,. Cancer statistics for African Americans. CA Cancer J Clin. 2013; 63: 151-166.
53. van Ravesteyn NT, Schechter CB, Near AM, et al. Race-specific impact of natural history, mammography screening, and adjuvant treatment on breast cancer mortality rates in the US. Cancer Epidemiol Biomarkers Prev. 2011; 20: 112-122.
54. Ansell D, Grabler P, Whitman S, et al. A community effort to reduce the black/white breast cancer mortality disparity in Chicago. Cancer Causes Control. 2009; 20: 1681-1688.
55. Gehlert S, Sohmer D, Sacks T, Mininger C, McClintock M, Olopade O,. Targeting health disparities: a model linking upstream determinants to downstream interventions. Health Aff (Millwood). 2008; 27: 339-349.
56. Press R, Carrasquillo O, Sciacca RR, Giardina EG,. Racial/ethnic disparities in time to follow-up after an abnormal mammogram. J Womens Health. 2008; 17: 923-930.
57. Silber JH, Rosenbaum PR, Clark AS, et al. Characteristics associated with differences in survival among black and white women with breast cancer. JAMA. 2013; 310: 389-397.
58. Gwyn K, Bondy ML, Cohen DS, et al. Racial differences in diagnosis, treatment, and clinical delays in a population-based study of patients with newly diagnosed breast carcinoma. Cancer. 2004; 100: 1596-1604.
59. Richards MA, Westcombe AM, Love SB, Littlejohns P, Ramirez AJ,. Influence of delay on survival in patients with breast cancer: a systematic review. Lancet. 1999; 353: 1119-1126.
60. McLaughlin JM, Anderson RT, Ferketich AK, Seiber EE, Balkrishnan R, Paskett ED,. Effect on survival of longer intervals between confirmed diagnosis and treatment initiation among low-income women with breast cancer. J Clin Oncol. 2012; 30: 4493-4500.
61. Li CI, Malone KE, Daling JR,. Differences in breast cancer stage, treatment, and survival by race and ethnicity. Arch Intern Med. 2003; 163: 49-56.
62. Griggs JJ, Culakova E, Sorbero ME, et al. Social and racial differences in selection of breast cancer adjuvant chemotherapy regimens. J Clin Oncol. 2007; 25: 2522-2527.
63. Freedman RA, He Y, Winer EP, Keating NL,. Trends in racial and age disparities in definitive local therapy of early stage breast cancer. J Clin Oncol. 2009; 27: 713-719.
64. Griggs JJ, Sorbero ME, Stark AT, Heininger SE, Dick AW,. Racial disparity in the dose and dose intensity of breast cancer adjuvant chemotherapy. Breast Cancer Res Treat. 2003; 81: 21-31.
65. Smith K, Wray L, Klein-Cabral M, et al. Ethnic disparities in adjuvant chemotherapy for breast cancer are not caused by excess toxicity in black patients. Clinical Breast Cancer. 2005; 6: 260-266.
66. Bickell NA, Wang JJ, Oluwole S, et al. Missed opportunities: racial disparities in adjuvant breast cancer treatment. J Clin Oncol. 2006; 24: 1357-1362.
67. Fisher B, Costantino J, Redmond C, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med. 1989; 320: 479-484.
68. Partridge AH, Wang PS, Winer EP, Avorn J,. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol. 2003; 21: 602-606.
69. Streeter SB, Schwartzberg L, Husain N, Johnsrud M,. Patient and plan characteristics affecting abandonment of oral oncolytic prescriptions. J Oncol Pract. 2011; 7 (3 suppl): 46s-51s.
70. Alberti PM, Kanani NS, Sutton K, Johnson BH, Holve E,. The state of health equity research: closing knowledge gaps to address inequities. members.aamc.org/eweb/upload/14-009%20HEALTH%20DISPARITIES-FINAL1.pdf. Accessed November 2014.
71. Wood WC, Budman DR, Korzun AH, et al. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med. 1994; 330: 1253-1259.
72. Budman DR, Berry DA, Cirrincione CT, et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. J Natl Cancer Inst. 1998; 90: 1205-1211.
73. Dignam JJ,. Efficacy of systemic adjuvant therapy for breast cancer in African-American and Caucasian women. J Natl Cancer Inst Monogr. 2001;2001: 36-43.
74. Hershman DL, Unger JM, Barlow WE, et al. Treatment quality and outcomes of African American versus white breast cancer patients: retrospective analysis of Southwest Oncology Studies S8814/S8897. J Clin Oncol. 2009; 27: 2157-2162.
75. Hassett MJ, Griggs JJ,. Disparities in breast cancer adjuvant chemotherapy: moving beyond yes or no. J Clin Oncol. 2009; 27: 2120-2121.
76. Tammemagi CM, Nerenz D, Neslund-Dudas C, Feldkamp C, Nathanson D,. Comorbidity and survival disparities among black and white patients with breast cancer. JAMA. 2005; 294: 1765-1772.
77. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM,. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA. 2006; 295: 1549-1555.
78. Griggs JJ, Sorbero ME, Lyman GE,. Undertreatment of obese women receiving breast cancer chemotherapy. Arch Intern Med. 2005; 165: 1267-1273.
79. Cohen SS, Palmieri RT, Nyante SJ, et al. Obesity and screening for breast, cervical, and colorectal cancer in women: a review. Cancer. 2008; 112: 1892-1904.
80. Elmore JG, Carney PA, Abraham LA, et al. The association between obesity and screening mammography accuracy. Arch Intern Med. 2004; 164: 1140-1147.
81. Curtis E, Quale C, Haggstrom D, Smith-Bindman R,. Racial and ethnic differences in breast cancer survival: how much is explained by screening, tumor severity, biology, treatment, comorbidities, and demographics? Cancer. 2008; 112: 171-180.
82. Anderson V,. The society's mission to reduce cancer health disparities. ASCO Connect. 2014: 10-15.
83. Lillie-Blanton M, Hoffman C,. The role of health insurance coverage in reducing racial/ethnic disparities in health care. Health Aff (Millwood). 2005; 24: 398-408.
84. Ayanian JZ, Kohler BA, Abe T, Epstein AM,. The relationship between health insurance coverage and clinical outcomes among women with breast cancer. N Engl J Med. 1993; 329: 326-331.
85. Coburn N, Fulton J, Pearlman DN, Law C, DiPaolo B, Cady B,. Treatment variation by insurance status for breast cancer patients. Breast J. 2008; 14: 128-134.
86. Voti L, Richardson LC, Reis I, Fleming LE, Mackinnon J, Coebergh JW,. The effect of race/ethnicity and insurance in the administration of standard therapy for local breast cancer in Florida. Breast Cancer Res Treat. 2006; 95: 89-95.
87. Baicker K, Taubman SL, Allen HL, et al. The Oregon experiment-effects of Medicaid on clinical outcomes. N Engl J Med. 2013; 368: 1713-1722.
88. Hoffman HJ, LaVerda NL, Levine PH, et al. Having health insurance does not eliminate race/ethnicity-associated delays in breast cancer diagnosis in the District of Columbia. Cancer. 2011; 117: 3824-3832.
89. Short LJ, Fisher MD, Wahl PM, et al. Disparities in medical care among commercially insured patients with newly diagnosed breast cancer: opportunities for intervention. Cancer. 2010; 116: 193-202.
90. Allen JD, Shelton RC, Harden E, Goldman RE,. Follow-up of abnormal screening mammograms among low-income ethnically diverse women: findings from a qualitative study. Patient Educ Couns. 2008; 72: 283-292.
91. Masi CM, Gehlert S,. Perceptions of breast cancer treatment among African-American women and men: implications for interventions. J Gen Intern Med. 2009; 24: 408-414.
92. Janz NK, Mujahid MS, Hawley ST, Griggs JJ, Hamilton AS, Katz SJ,. Racial/ethnic differences in adequacy of information and support for women with breast cancer. Cancer. 2008; 113: 1058-1067.
93. Hawley ST, Fagerlin A, Janz NK, Katz SJ,. Racial/ethnic disparities in knowledge about risks and benefits of breast cancer treatment: does it matter where you go? Health Serv Res. 2008; 43: 1366-1387.
94. Albano JD, Ward E, Jemal A, et al. Cancer mortality in the United States by education level and race. J Natl Cancer Inst. 2007; 99: 1384-1394.
95. Lannin DR, Matthews HF, Mitchell J, Swanson MS,. Impacting cultural attitudes in African-American women to decrease breast cancer mortality. Am J Surg. 2002; 184: 418-423.
96. Hurtado-de-Mendoza A, Song M, Kigen O, Nwabukwu I, Sheppard VB,. Addressing cancer control needs of African-born immigrants in the US: a systematic literature review. Prev Med. 2014; 67: 89-99.
97. Piwowarczyk L, Bishop H, Saia K, et al. Pilot evaluation of a health promotion program for African immigrant and refugee women: the UJAMBO program. J Immigr Minor Health. 2013; 15: 219-223.
98. Percac-Lima S, Ashburner JM, Bond B, Oo SA, Atlas SJ,. Decreasing disparities in breast cancer screening in refugee women using culturally tailored patient navigation. J Gen Intern Med. 2013; 28: 1463-1468.
99. Ko NY, Darnell JS, Calhoun E, et al. Can patient navigation improve receipt of recommended breast cancer care? Evidence from a national patient navigation research program. J Clin Oncol. 2014; 32: 2758-2764.
100. Vargas RB, Ryan GW, Jackson CA, Rodriguez R, Freeman HP,. Characteristics of the original patient navigation programs to reduce disparities in the diagnosis and treatment of breast cancer. Cancer. 2008; 113: 426-433.
101. Markossian TW, Darnell JS, Calhoun EA,. Follow-up and timeliness after an abnormal cancer screening among underserved, urban women in a patient navigation program. Cancer Epidemiol Biomarkers Prev. 2012; 21: 1691-1700.
102. Hoffman HJ, LaVerda NL, Young HA, et al. Patient navigation significantly reduces delays in breast cancer diagnosis in the District of Columbia. Cancer Epidemiol Biomarkers Prev. 2012; 21: 1655-1663.
103. Ferrante JM, Chen PH, Kim S,. The effect of patient navigation on time to diagnosis, anxiety, and satisfaction in urban minority women with abnormal mammograms: a randomized controlled trial. J Urban Health. 2008; 85: 114-124.
104. Tejeda S, Darnell JS, Cho YI, Stolley MR, Markossian TW, Calhoun EA,. Patient barriers to follow-up care for breast and cervical cancer abnormalities. J Womens Health. 2013; 22: 507-517.
105. Clarke AR, Goddu AP, Nocon RS, et al. Thirty years of disparities intervention research: what are we doing to close racial and ethnic gaps in health care? Med Care. 2013; 51: 1020-1026.
106. Bickell NA, Shastri K, Fei K, et al. A tracking and feedback registry to reduce racial disparities in breast cancer care. J Natl Cancer Inst. 2008; 100: 1717-1723.
107. Grubbs SS, Polite BN, Carney J, et al. Eliminating racial disparities in colorectal cancer in the real world: it took a village. J Clin Oncol. 2013; 31: 1928-1930.
108. Fox J,. Lessons from an oncology medical home collaborative. Am J Manag Care. 2013; 19: SP5-SP9.
109. Mehta AJ, Macklis RM,. Overview of accountable care organizations for oncology specialists. J Oncol Pract. 2013; 9: 216-221.
110. Daly B, Mort EA,. A decade after to err is human: what should health care leaders be doing? Physician Exec. 2014; 40: 50-52.
111. Dangi-Garimella S,. Oncology medical home: improved quality and cost of care. Am J Manag Care. 2014; 20: SP391.
112. McAneny BL,. The future of oncology? Come home, the oncology home. Am J Manag Care. 2013; 19: SP41-SP42.
113. Goyal RK, Wheeler SB, Kohler RE, et al. Health care utilization from chemotherapy-related adverse events among low-income breast cancer patients: effect of enrollment in a medical home program. N C Med J. 2014; 75: 231-238.
114. Kuntz G, Tozer JM, Snegosky J, Fox J, Neumann K,. Michigan oncology medical home demonstration project: first-year results. J Oncol Pract. 2014; 10: 294-297.
115. Moy B, Polite BN, Halpern MT, et al. American Society of Clinical Oncology policy statement: opportunities in the Patient Protection and Affordable Care Act to reduce cancer care disparities. J Clin Oncol. 2011; 29: 3816-3824.
116. Chin MH, Clarke AR, Nocon RS, et al. A roadmap and best practices for organizations to reduce racial and ethnic disparities in health care. J Gen Intern Med. 2012; 27: 992-1000.
117. Zhang SQ, Polite BN,. Achieving a deeper understanding of the implemented provisions of the Affordable Care Act. Am Soc Clin Oncol Educ Book. 2014: e472-e477.
118. Polite BN, Sylvester BE, Olopade OI,. Race and subset analyses in clinical trials: time to get serious about data integration. J Natl Cancer Inst. 2011; 103: 1486-1488.
119. Hall MJ, Olopade OI,. Disparities in genetic testing: thinking outside the BRCA box. J Clin Oncol. 2006; 24: 2197-2203.
120. Churpek JE, Walsh T, Zheng Y, et al. Inherited mutations in breast cancer genes in African American breast cancer patients revealed by targeted genomic capture and next-generation sequencing [abstract]. J Clin Oncol. 2013; 31 (suppl): CRA1501.
121. Easton J,. Genetic mutations more common among African American women with breast cancer: early testing could protect patients and their relatives. news.uchicago.edu/article/2013/06/03/genetic-mutations-more-common-among-african-american-women-breast-cancer. Published June 3, 2013. Accessed August 1, 2014.
122. Pear R,. U.S. to collect genetic data to hone care. New York Times. January 30, 2015.
123. Junger S,. The Perfect Storm. New York, NY: WW Norton and Co; 2009.